CureVac and MD Anderson enter strategic collaboration to develop novel cancer vaccines
Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need
17-Apr-2024 -
CureVac N.V. and The University of Texas MD Anderson Cancer Center announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
The collaboration creates strong synergies between CureVac’s unique end-to-end capabilities for cancer antigen discovery, mRNA design, ...
cancer
cancer vaccines
mRNA vaccines
+1